News

Roche's Wilserdly-Everolimus Gets FDA Approval For ESR1-Mutated Advanced Breast Cancer

NASDAQ

(RTTNews) - Roche Holding AG (RHHBY) said the U.S. Food and Drug Administration approved Wilserdly, or giredestrant, with everolimus for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.